Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02068573
Other study ID # AstmaVen - 1101
Secondary ID
Status Completed
Phase N/A
First received February 19, 2014
Last updated May 11, 2016
Start date August 2012
Est. completion date February 2016

Study information

Verified date May 2016
Source University of Aarhus
Contact n/a
Is FDA regulated No
Health authority Denmark: Danish Dataprotection Agency
Study type Interventional

Clinical Trial Summary

AsthmaVent is a multi-center study, investigating the association between indoor air quality and childhood asthma.

In Denmark, we spend more and more time indoors. Our houses are built airtight to save energy and are difficult to ventilate. We are thus more exposed to our indoor air than ever before. We know that indoor air contains many different components that can affect our airways inappropriately and particularly children with asthma, who have sensitive airways are sensitive to these components. The AsthmaVent project examines whether increased ventilation is able to improve the indoor environment to such an extent that the asthma disease control, for children with asthma and house dust mite allergy improves, resulting in need for less medication.

Previous studies have pointed towards a beneficial effect of mechanical ventilation, on both the indoor air quality and on children's health and quality of life. There is not currently a consensus in this area, as studies so far have not been large or good enough to confidently determine the effect.

This project is big and is designed so that it takes into account the sources of error seen in previous studies on the topic.

We include, over a 3-year period (2012-2014), a total of 80 children with asthma and house dust mite allergy aged 6-18 years, from pediatric departments in Aarhus, Odense, Kolding, Randers and Herning. They are divided into two groups, receiving either active ventilation or placebo ventilation, meaning a non-functioning ventilation system that just recirculates the air in the room. Ventilation systems are installed in the fall and winter and ventilate the child's bedroom during 9 months. Indoor air quality and asthma control are assessed every 3 months, both at home visits were air quality and allergen levels of house dust mites are studies and at visits to the outpatient clinics with control of asthma parameters and quality of life.

The project involves collaboration between several institutions with an interest in indoor air quality in relation to allergies and asthma and with great expertise in the field.The project was initiated by CISBO (Centre for Indoor Environment and Health in Dwellings), a center consisting of several institutions in Denmark dealing with indoor environment: Department of Public Health at Aarhus University and University of Copenhagen, Danish Building Research Institute and the Technical University of Denmark.

Since asthma is the most common chronic childhood disease in Denmark and since the development of allergies and asthma has high social and personal costs, it is important for both society and the individual family, to find out whether simply improving the indoor air quality by increased ventilation can lead to an improvement in asthma disease control.


Description:

The aim of the project is to investigate whether increased ventilation is able to improve the indoor air quality and thereby asthma disease control for children with asthma and house dust mite allergy.

Hypotheses:

1. An increased ventilation in the home will reduce the need for inhaled steroids in children with house dust mite allergy and asthma.

2. An increased ventilation in the home will improve the quality of life in children with house dust mite allergy and asthma.

3. An increased ventilation in the home will improve the indoor environment and thus improve asthma disease control in children with house dust mite allergy and asthma.

Materials and methods: The study is a randomized double-blind placebo-controlled intervention study. The intervention is balanced mechanical ventilation in the bedroom of children with asthma and house dust mite allergy during 9-months.

Population: Over 3 year period (2012-2014) 80 families with asthmatic children aged 6-18 years will be included from out-patient clinics at the children's department of the University Hospitals of Aarhus and Odense and regional hospitals in Kolding, Randers and Herning. Families will also be included from private pediatric clinics in Aarhus.

Randomization: After inclusion children are randomized to either active ventilation or placebo ventilation. Randomization is done in blocks of 4 by center.

Intervention: The ventilation units Type DUPLEX 370 EC4.D and DUPLEX 370 are installed during the fall and run continuously for 9 months. The ventilation system is placed outside the house and provides filtered conditioned air to the child's bedroom, through insulated pipes mounted in a window opening. The window opening was built specifically for this purpose in form of a thermo plate replacing the window glass. The unit provides the bedroom with at least 2-3 air changes per hour. The placebo unit (DUPLEX 370) is a completely similar installation which only recirculates the air in the room instead of replacing it. We recommend all parents to wash the duvet and pillow every 3 months.

Data collection:

Data on the children's health is collected every 3 months when the families visit the outpatient clinics. The children are seen by specialist doctors.

At home visits, also every 3 months, data concerning the indoor air quality is collected.


Recruitment information / eligibility

Status Completed
Enrollment 46
Est. completion date February 2016
Est. primary completion date February 2016
Accepts healthy volunteers No
Gender Both
Age group 5 Years to 18 Years
Eligibility Inclusion Criteria:

- Doctors diagnosed asthma

- Need of inhaled steroid titrated down to at least 400 microg/day of Budesonide or equivalent dose of other corticosteroid

- Skin prick test >/= 3 mm or specific IgE >/= 0,7 kU/l to house dust mites (Derm. Pteronyssinus and/or Derm. Farinae)

- more than 500 nanog/gr dust of house dust mite allergen in the childs mattress.

- Living in a one-family house and will allow changes of the house during the intervention period.

- Capable of giving informed consent.

Exclusion Criteria:

- Other clinically relevant allergies to tree pollen or animals present in the house.

- Other diseases or treatments, as for example immunotherapy, which could influence the results.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Ventilation
The ventilation system is placed outside the house and provides filtered conditioned air to the child's bedroom, through insulated pipes mounted in a window opening. The window opening was built specifically for this purpose in form of a thermo plate replacing the window glass. The unit provides the bedroom with at least 2-3 air changes per hour
Placebo Ventilation
The placebo unit (DUPLEX 370) is a completely similar installation to the active ventilation unit, but it only recirculates the air in the room instead of replacing it with fresh conditioned air.

Locations

Country Name City State
Denmark Childrens Department, Aarhus University Hospital Aarhus Region Midt
Denmark Børneafdelingen Herlev Hospital Herlev Region Hovedstaden
Denmark Childrens Department, Herning Hospital Herning Region Midt
Denmark Childrens Department, Hillerød hospital Hillerød Region Nordsjælland
Denmark Childrens Department, Kolding Hospital Kolding Region Syddanmark
Denmark H.C. Andersens Children Hospital, Odense University Hospital Odense Region Syddanmark
Denmark Childrens DEpartment, Randers Hospital Randers Region Midt

Sponsors (1)

Lead Sponsor Collaborator
University of Aarhus

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in dose of inhaled corticosteroid Measured in micrograms of a specific inhaled corticosteroid Baseline, 3 months, 6 months and 9 months No
Primary Changes in particle concentration in child bedroom Measured as particles pr. m3 baseline, 3 months, 6 months and 9 months No
Secondary FEV1 Forced Expiratory Volume after 1 second Baseline, 3,6 and 9 months No
Secondary FeNO Forced Expiratory Nitric Oxide Baseline, 3,6 and 9 months No
Secondary Quality of Life Pediatric Asthma Quality of Life Questionaire Baseline, 3,6 and 9 months No
Secondary Standard Skin-prick-test and Specific IgE- phadiatop Reduction in diameter of skin-prick-test for standard inhalant allergens and reduction in specific IgE for standard inhalant allergens measured in kU/l. Baseline and 9 months No
Secondary Asthma Symptoms Assessed from a Symptom score scheme During 14 days at baseline, 3, 6 and 9 months No
Secondary Peakflow variability Baseline, 3, 6 and 9 months No
Secondary Ventilation rate Ventilation rate in the childs bedroom and in the Whole house Baseline, 3, 6 and 9 months No
Secondary Physical conditions in the child bedroom and whole house Changes in temperature and humidity baseline, 3 6 and 9 months No
Secondary Allergens in child mattress and airborne in child bedroom Reduction in allergen levels. baseline, 3, 6 and 9 months No
See also
  Status Clinical Trial Phase
Terminated NCT02032056 - Effect of Probiotics in Reducing Infections and Allergies in Young Children During the Complementary Feeding Period N/A
Completed NCT01842711 - Cumulative Irritation Patch Test N/A
Completed NCT01633840 - New Validated Recipes for Double-blind Placebo-controlled Low Dose Food Challenges N/A
Completed NCT00554983 - Efficacy and Safety From a Recombinant Folding Variant of Bet v 1 Phase 3
Completed NCT00997971 - Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein Phase 3
Completed NCT00331929 - Respiratory Health Study of Children in Kiryat Tivon N/A
Completed NCT00220753 - Air Cleaners for Children and Adolescents With Asthma and Dog Allergy N/A
Completed NCT00232518 - Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis N/A
Completed NCT04046731 - Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation N/A
Completed NCT04126096 - Negative Predictive Value and NIC of Beta-Lactam Antibiotics. N/A
Completed NCT04004351 - Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma
Not yet recruiting NCT05997784 - Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing
Completed NCT04418999 - Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus Early Phase 1
Completed NCT04186949 - Early Origins of Allergy and Asthma
Completed NCT02127801 - Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants Phase 1
Enrolling by invitation NCT05011071 - The Alberta BLOOM Premature Child Study
Not yet recruiting NCT06330974 - Allergy, Asthma, and Atopic Eczema in Finland
Completed NCT02306473 - The Leaky Lung Test Early Phase 1
Completed NCT02596321 - A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma Phase 3
Terminated NCT02601690 - Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America